

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE MEDICINAL PRODUCT

Rexocef® 100 mg film-coated tablets.
Rexocef® 200 mg film-coated tablets.

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Rexocef 100 mg film-coated tablets

Each film-coated tablet contains 100 mg cefpodoxime as cefpodoxime proxetil.
Excipients: each tablet contains 9 mg lactose monohydrate.

Rexocef 200 mg film-coated tablets

Each film-coated tablet contains 200 mg cefpodoxime as cefpodoxime proxetil.
Excipients: each tablet contains 18 mg lactose monohydrate.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

* Film-coated tablet.

Rexocef 100 mg film-coated tablets are white to off white, round, biconvex tablets with "100" debossed on one side and plain on the other side. The dimension of each tablet is 8.5 mm.

Rexocef 200 mg film-coated tablets are white to off white, round, biconvex tablets with "200" debossed on one side and plain on the other side. The dimension of each tablet is 11.0 mm.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Rexocef film-coated tablets are indicated for the treatment of the following infections when caused by bacteria susceptible to cefpodoxime (see section 5.1) in adults and adolescents from 12 years of age.

Ear, nose and throat infections:

- tonsillitis, pharyngitis;
- sinusitis.

Lower respiratory tract infections:

- Acute exacerbation of chronic bronchitis (AECB);

- Bacterial pneumonia;

Urinary tract infections:

- Acute non-complicated pyelonephritis;
- Acute non-complicated cystitis in women;
- Acute non-complicated gonococcal urethritis in men and cervicitis in women.

Infections of the skin and the soft tissue.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

4.2 Posology and method of administration

Posology

For adults and adolescents above 12 years of age, depending on the type of disease, the following dosing is recommended: see Table 1

The usual single dose of Rexocf should be taken in the time interval of 12 hours.
Exceptions are patients with renal impairment (see below).

For the treatment of gonococcal urethritis/cervicitis, independently of the renal impairment, a single dose of 200 mg cefpodoxime is prescribed.

Success of the therapy should be checked 3-4 days after the completion of the therapy with microbiologic diagnostics.

Table 1: Dosing of Rexocf 100 mg & 200 mg film coated tablets

| TYPE OF DISEASE | Number of Rexocf 100 mg film coated tablets | Number of Rexocf 200 mg film coated tablets | Corresponds to mg cefpodoxime a day |
|--|---|--|-------------------------------------|
| | In time interval of 12 hours | In time interval of 12 hours | |
| Tonsillitis, pharyngitis | 2 times 1 tablet each | For this indication you should use Rexocf 100 mg film coated tablets | 200 mg |
| Sinusitis | 2 times 2 tablets each | 2 times 1 tablet each | 400 mg |
| Acute exacerbation of chronic bronchitis | 2 times 2 tablets each | 2 times 1 tablet each | 400 mg |
| Bacterial pneumonia | 2 times 2 tablets each | 2 times 1 tablet each | 400 mg |
| Acute non-complicated pyelonephritis | 2 times 2 tablets each | 2 times 1 tablet each | 400 mg |
| Acute non-complicated cystitis in women | 2 times 1 tablet each | For this indication you should use Rexocf 100 mg | 200 mg |



| | | film coated tablets | |
|---|------------------------|-----------------------|--------|
| Acute non-complicated gonococcal urethritis in men and cervicitis in women* | One dose of 2 tablets | One dose of 1 tablet | 200 mg |
| Infections of the skin and the soft tissue | 2 times 2 tablets each | 2 times 1 tablet each | 400 mg |

** Success of the therapy in acute uncomplicated gonococcal urethritis in men and gonococcal infection of the cervix in women should be checked 3-4 days after the completion of the therapy with microbiologic diagnostics.*

Dosing in patients with renal impairment

- Patients with creatinine clearance below 40 to 10 ml / min / 1.73 m² should receive **one dose of the medicine** (100 or 200 mg cefpodoxime) **on every 24 hours**.
- Patients with creatinine clearance below 10 ml / min / 1.73 m² should receive **one dose of the medicine** (100 or 200 mg cefpodoxime) **on every 48 hours**.
- Patients on haemodialysis should receive **one dose of the medicine** (100 or 200 mg cefpodoxime) **after each dialysis**.

In patients with liver impairment and in elderly patients with normal renal function, adjustment of the dose is not required.

Duration of treatment

The duration of the therapy is usually 5 - 10 days, except with therapy of acute uncomplicated gonococcal urethritis in men and cervicitis in women (single dose).

When treating infections caused by *Streptococcus pyogenes* the duration of the therapy is at least 10 days in order to prevent further complications such as rheumatic fever or occurrence of severe renal disease, glomerulonephritis.

Method of Administration


For oral administration.

Rexocef film coated tablets should be taken with sufficient amount of liquid (e.g. a glass of water) after meal, because then the active ingredient is best absorbed in the body.

4.3 Contraindications

Hypersensitivity to the active substance Cefpodoxime proxetil, to other cephalosporins or to any of the excipients.

Previously known hypersensitivity Type 1 or severe hypersensitive reactions, anaphylaxis to penicillin or to other beta-lactam antibiotics.



4.4 Special warnings and precautions for use

Special caution should be exercised when giving REXOCEF film coated tablets to patients hypersensitive to penicillin or other β -lactam antibiotics, because of possible allergic cross-reactivity (for contraindications with known reactions to hypersensitivity see section 4.3)

When using REXOCEF film coated tablets, special attention should also be taken with patients with allergic diathesis or asthma, because in these cases the risk of occurrence of severe hypersensitivity reactions is increased.

During the administration of REXOCEF film coated tablets, hypersensitivity reactions with different severity of clinical features up to the anaphylactic shock may occur (see section 4.8).

Upon the occurrence of severe hypersensitivity reactions, the therapy with REXOCEF should be discontinued immediately and adequate therapy should be given.

In severe gastrointestinal disorders, accompanied with vomiting and diarrhoea, treatment with REXOCEF film coated tablets should be avoided, since the absorption into the gastrointestinal tract will not be sufficient.

During the therapy with REXOCEF film coated tablets or afterwards, inflammation of the colon may occur (e.g. pseudomembranous colitis) characterised with severe and persistent diarrhoea that sometimes may be life-threatening. In such a case, the therapy with REXOCEF film coated tablets should be discontinued immediately and adequate therapy should be given.

Use of medicines that inhibit the peristaltic is contraindicated.

Use of REXOCEF film coated tablets may induce vomiting and diarrhoea (see section 4.8). In this case, the efficiency of this and/or other medicines (e.g. oral contraceptives) can be reduced.

Long-term or repeated use of REXOCEF film coated tablets may cause superinfection and colonisation with resistant bacteria or fungi (e.g. oral candidiasis, vaginitis).

Erythema multiforme, Stevens-Johnson syndrome, Lyell syndrome:

If these conditions occur, the use of the drug should be discontinued immediately.

Patients with renal impairment

In patients with creatinine clearance above 40 ml/min change of the dose is not required. In patients with creatinine clearance below 40 ml/min and in patients treated with haemodialysis, extension of the time interval between the doses is required (see section 4.2 Dosing, administration and time of use).


Effects on the clinical and chemical parameters

During the treatment with cephalosporins both the Coomb's test and the non-enzymatic methods for glucose determination in the urine can show false-positive results.

REXOCEF film-coated tablets contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.

4.5 Interaction with other medicaments and other forms of interaction

With parenteral administration of high cephalosporin doses and concurrent use of strong diuretics (e.g. furosemide) or potentially **nephrotoxic drugs** (eg. aminoglycoside antibiotics) possibility for impairment of the renal function cannot be excluded. However, pharmacological data and clinical



experience show that it is not likely to occur with the use of the recommended doses of Rexocef film coated tablets.

Antacids and H2-blockers

Concurrent administration of preparations that increase the pH value in the stomach and cefpodoxime in volunteers on an empty stomach, decreased the bioavailability of cefpodoxime by about 30%. Studies carried out so far have shown the following results:

Antacids

Aluminium hydroxide – 27%

Sodium bicarbonate – 32%

H2-blockers

Ranitidine – 29%

Therefore, these medicines should be taken 2 - 3 hours before or after the use of Rexocef film coated tablets.

Bacteriostatic antibiotics

Rexocef film coated tablets should not be used concomitantly with bacteriostatic antibiotics (such as chloramphenicol, erythromycin, sulfonamides, and tetracyclines), because the effect of Rexocef film coated tablets can be reduced.

4.6 Fertility, pregnancy and lactation

Pregnancy

There is no adequate data on the use of cefpodoxime proxetil in pregnancy. Studies carried out on animals have not shown evidence for teratogenic or fetotoxic effects of cefpodoxime. Because of the lack of clinical experience, in particular in the first three months of pregnancy, Rexocef film coated tablets should be prescribed only after careful assessment and taking into account the risk from their use.

Breast-feeding

The active ingredient cefpodoxime proxetil passes into breast milk in small amounts. In breastfed infants it can lead to change in the intestinal flora accompanied with diarrhoea and parasite colonisation of the bowels, so the breastfeeding will have to be discontinued. In addition, possibility of sensitisation should also be considered. Therefore, Rexocef film coated tablets should be used only after careful assessment and taking into account the risk from their use.

4.7 Effects on ability to drive and use machines

Experience so far shows that Rexocef film coated tablets do not influence the ability to react and concentration. Still, in rare cases, side effects such as hypotension or dizziness can reduce the ability to perform the stated activities (see section 4.8 Possible side effects).

APPROVED BY SCDMTE JSC

Expert / Date 28.11.18 *FS*Applicant / Date *Jelupium***4.8 Undesirable effects**

The side effects are grouped as follows:


| Common ≥ 1/100 to < 1/10 | Uncommon ≥ 1/1.000 to < 1/100 | Rare ≥ 1/10.000 to < 1/1.000 |
|---|---|---|
| Infections and infestations | | |
| Superinfections with unsusceptible microorganisms, e.g. fungi - Candida (see section 4.4) | | |
| Blood and lymphatic system disorders | | |
| | Thrombocytosis In most cases this change is reversible after the discontinuation of the therapy. | Agranulocytosis, hemolytic anemia, eosinophilia, lymphocytosis, anemia, leukopenia, neutropenia, leukocytosis, thrombocytopenia |
| Immune system disorders | | |
| | | Hypersensitive reactions of different levels of severity like angioedema, bronchospasm to the life threatening shock (see section 4.4). |
| Metabolism and nutrition disorders | | |
| Anorexia | | |
| Nervous system disorders | | |
| | Headache, paraesthesia, and dizziness. | |
| Ear and labyrinth disorders | | |

APPROVED BY SCDMTE JSC

Expert / Date 22.11.18 RS

Applicant / Date Jelufarum

| | | |
|---|---|---|
| | Tinnitus | |
| Gastrointestinal disorders | | |
| Stomach pains, nausea, vomiting, flatulence, or diarrhoea. | | Pseudomembranous enterocolitis (see section 4.4) Acute pancreatitis |
| Hepatobiliary disorders | | |
| | Increase of the hepatic enzymes concentration (transaminases, alkaline phosphatases) and/or bilirubin as a result of hepatic disorder (eg. cholestatic) | Acute hepatitis |
| Skin and subcutaneous tissue disorders | | |
| | Skin lesions with or without itching (erythema, exanthema, urticaria, purpura) Pruritus | Erythema multiforme, Stevens-Johnson syndrome, Lyell syndrome |
| Renal and urinary system disorders | | |
| | | Increased serum urea and creatinine concentrations Acute renal insufficiency |
| General disorders and administration site conditions | | |
| | Asthenia, fatigue, and malaise | |



4.9 Overdose

There have been no cases of significant overdose in people. Overdosing in adults with the daily dose up to 1000 mg cefpodoxime has been reported in few cases. Side effects were the same as those that can occur with the use of usually recommended doses. Cefpodoxime is dialysable.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmaco-therapeutic group: Third-generation cephalosporins.

ATC code: J01DD13.

Cefpodoxime proxetil, i.e. the ester of cefpodoxime, is a beta-lactam antibiotic from the group of cephalosporins for peroral administration.

Mechanism of action

Cefpodoxime acts by inhibiting the synthesis of the bacterial cell wall (in the growth phase) through blocking the penicillin-binding proteins (PBP), such as trans peptidases. This results in bactericidal activity.

Relation between the pharmacokinetics and the pharmacodynamics of the drug

The efficacy mainly depends on the period in which the level of concentration of cefpodoxime in the serum is above the minimum inhibitory concentration (MIC) of the pathogen.

Mechanisms of Resistance

The resistance to cefpodoxime can be caused by some of the following mechanisms:


- Inactivation with beta-lactamase: Cefpodoxime may be hydrolysed with certain beta-lactamases, especially with the so called wide spectrum beta-lactamases (ESBLs) that were discovered in *Escherichia coli* and *Klebsiella pneumoniae*, or through chromosome-encoded beta-lactamases of the AmpC type, for example, found in *Enterobacter cloacae*. In infections caused by bacteria with inducible AmpC-type of beta-lactamase and *in-vitro* susceptibility to cefpodoxime, there is a possibility for bacterial mutation and expression of the AmpC-type of beta-lactamase.
- Decrease of the affinity of the penicillin-binding proteins (PBP) to cefpodoxime: Acquired resistance of pneumococcus and other streptococcus types is based on the modification of PBP after mutation. However, the resistance to methicillin (oxacillin) resistant staphylococcus is attributed to the formation of additional PBP with decreased affinity for cefpodoxime.
- Decreased penetration of cefpodoxime through the cell wall of gram-negative bacteria, which results in the insufficient access of cefpodoxime to the penicillin-binding proteins.
- Presence of efflux pump that actively transports cefpodoxime out of the bacteria.

There is a partial or complete cross-resistance between cefpodoxime and other cephalosporins and penicillins.

Breakpoints:

The cefpodoxime test was performed using the standard dilution series. The following minimum inhibitory concentrations for sensitive and resistant bacteria have been identified:

EUCAST (European Committee on Antimicrobial Susceptibility Testing) breakpoints



| Pathogenic microorganism | Susceptible | Resistant |
|--|----------------------------|-------------------------|
| <i>Enterobacteriaceae</i> ¹⁾ | $\leq 1 \text{ mg/l}^{1)}$ | $> 1 \text{ mg/l}^{1)}$ |
| <i>Staphylococcus</i> spp. ²⁾ | - ²⁾ | - ²⁾ |
| <i>Streptococcus</i> spp. (Group A,B,C, and G) ³⁾ | - ³⁾ | - ³⁾ |
| <i>Streptococcus pneumoniae</i> | $\leq 0.25 \text{ mg/l}$ | $> 0.5 \text{ mg/l}$ |
| <i>Haemophilus influenzae</i> | $\leq 0.25 \text{ mg/l}$ | $> 0.5 \text{ mg/l}$ |

1) Only for uncomplicated urinary tract infections

2) For *Staphylococcus* spp. the result from the test for oxacillin or cefoxitin is taken. Methicillin (oxacillin) resistant staphylococci are considered resistant, regardless of the test results.

3) For *Streptococcus* spp. (Groups A, B, C, G) the result from the test for the penicillin G is taken.

Susceptibility and resistance

Prevalence of acquired resistance can vary geographically and temporally for certain species. Thus, it is desirable to have the local information on resistance available, especially when severe infections should be treated. When required, advice from an expert should be sought, if due to the local prevalence of the resistance the efficacy of cefpodoxime proxetil is compromised. In particular, in cases of serious infections or failure of the treatment, it is desirable to make microbiological diagnosis and determine which pathogen caused the infection and its susceptibility to cefpodoxime.

Usually susceptible species:

Aerobic gram-positive microorganisms

Staphylococcus aureus (Methicillin susceptible)

Streptococcus pneumoniae

Streptococcus pyogenes

Aerobic Gram -negative microorganisms

Haemophilus influenzae

Neisseria gonorrhoeae^o

*Proteus mirabilis*²⁾

Species with which acquired resistance may be a problem:

Aerobic gram-positive microorganisms

Staphylococcus aureus ^{S³}

Staphylococcus epidermidis ^{S⁺}

Staphylococcus haemolyticus ^{S⁺}

Staphylococcus hominis ^{S⁺}

Staphylococcus saprophyticus ^S

Streptococcus pneumoniae (Penicillin-intermediary)

**Aerobic Gram-negative microorganisms**

Citrobacter freundii §
Enterobacter cloacae §
Escherichia coli % & §
Klebsiella pneumoniae %
Moraxella catarrhalis §
Serratia marcescens §

Naturally resistant species:**Aerobic gram-positive microorganisms**

Enterococcus spp.
Staphylococcus aureus (Meticillin-resistant)
Streptococcus pneumoniae (Penicillin-resistant)

Aerobic Gram-negative microorganisms

Morganella morganii
Pseudomonas aeruginosa

Other microorganisms

Chlamydia spp.
Chlamydophila spp.
Legionella pneumophila
Mycoplasma spp.

° Current data was not available at the time of publishing of the table. The conclusion on the susceptibility of the species is derived from the recommendations in literature and usual recommendations for the therapy.

§ Natural susceptibility of the most of isolates is within the intermediate range.

+ In at least one region, the resistance rate is above 50%.

% Strains that produce wide spectrum β -lactamases (ESBLs) are always resistant.

& In isolates from patients with uncomplicated cystitis, the rate of resistance is <10 %, otherwise it is $\geq 10\%$.

§ In hospital conditions, the rate of resistance is <10%.

5.2 Pharmacokinetic properties


Cefpodoxim proxetil is a prodrug of cefpodoxim.

Resorption

Upon oral administration, cefpodoxim is absorbed in the gastrointestinal tract and is quickly hydrolysed in the intestinal mycosis into cefpodoxim.

Distribution**Children**

After oral administration of a dose of 5 mg cefpodoxim * / kg body weight (maximum 200 mg *) in children between 4 and 12 years the average (T_{max}) was 2 - 4 hours. Maximum plasma levels (C_{max}) is 2.6 mg / l. The average plasma concentrations, 8 and 12 hours after administration, were 0.39 and 0.08 mg / l, respectively.

Single-dose in adults

After a single oral dose of 100 mg of cefpodoxim* maximum plasma concentration (C_{max}) is from 1 to 1,2 mg/l, and following the single dose of 200 mg of cefpodoxim* C_{max} is 2.2 to 2.5 mg/l. In both cases (100 mg/200 mg) C_{max} is reached in 2 to 3 hours (T_{max}).

Repeated doses in adults

With repeated doses of 100 or 200 mg cefpodoxim* within the time intervals of 12 hours during 14.5 days, the pharmacokinetic parameters have not shown any changes and occurrence of accumulation.

Elderly patients

In patients at the age of 70 and older, after repeated dosing of cefpodoxim* of 200 mg within 12-hour time intervals during 6 to 10 days, a steady state is reached. In the steady state C_{max} is 3.05 mg/l and T_{max} is 2.7 hours on average.

Patients with liver cirrhosis

After a single dose of 200 mg cefpodoxim* in patients with cirrhosis with or without ascites, C_{max} is about 1.67 mg/l, what corresponds to the C_{max} 12 hours after the administration of the drug to healthy volunteers.

Patients with chronic renal insufficiency

Plasma concentration of the drug in patients with chronic renal insufficiency, depends on the severity of the renal insufficiency. With persons with the creatinine clearance below 40 ml / min (10-40 ml / min), C_{max} after the administered dose of 200 mg cefpodoxime* is twice as high as in healthy volunteers on average, while the T_{max} is around 4 hours.

* Administered as cefpodoxime proxetil

Hemodialysis patients

Plasma concentration of the drug in patients with creatinine clearance below 10 ml/min (10 ml / min) is 1.5 times higher than in healthy volunteers on average while T_{max} is around 6 hours. Cefpodoxime is dialyzable; therefore a single dose of the drug has to be administered immediately after the haemodialysis.

Distribution volume

The distribution volume is 32.3 l in young subjects (+ 0.43 l / kg).

Plasma protein binding

The plasma protein binding is essentially based on albumins and is about 40%. This binding is not saturable.


Tissue distribution

Cefpodoxim diffuses well in lung parenchyma, bronchial mucosa, pleural fluid, tonsils, kidney, prostate and interstitial fluids. The observed concentrations are higher than the MIC values for susceptible pathogenic microorganisms.

Metabolism and elimination

After the absorption, cefpodoxime proxetil is hydrolysed to the main metabolite cefpodoxime. Cefpodoxime is difficult to metabolise and 80% of cefpodoximeproxetil is excreted through the kidneys unchanged.

Total clearance of cefpodoxime is 9.98 l/h, while the renal clearance is 7 l/h on average.



The half-life of elimination ($T_{1/2}$) of cefpodoxime is 2.4 hours.

In elderly patients, the half-life of elimination ($T_{1/2}$) is extended to 3.6 hours on average.

In patients with chronic renal insufficiency and the creatinine clearance below 40 ml/min, $T_{1/2}$ is more than 6 hours (7.7 hours on average in creatinine clearance between 10 and 40 ml/min).

Absolute bioavailability

The absolute bioavailability of cefpodoxime is approximately 40 - 50% after oral administration of a tablet of cefpodoxim proxetil (equivalent to 100 mg cefpodoxim) on an empty stomach.

The absorption is increased by concomitant intake of a meal, therefore the tablets should be administered with a meal.

5.3 Preclinical safety data

There are no findings on the chronic toxicity that would lead to suspicion that unknown effects with human use could occur.

Moreover, teratogenic or mutagenic potential has not been determined in *in vivo* or in *in vitro* studies.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Tablet core:

Lactose monohydrate

Magnesium stearate

Carmellose calcium

Low substituted hydroxypropylcellulose

Sodium laurilsulfate

Film coating

Opadry white, containing:

Hypromellose (E464)

Titanium dioxide (E171)

Talc

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

2 years.

6.4 Special precautions for storage

Store below 25°C.



6.5 Nature and contents of container

The tablets are immediate packed in oPA/Al/PVC-Al blister packs, containing 10 tablets in each blister. The cardboard box contains 10 tablets (1 blister) or 20 tablets (2 blisters) and an instruction leaflet.

6.6 Special precautions for disposal and other handling

No special requirements.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

ALKALOID AD Skopje
Blvd. Aleksandar Makedonski 12
1000 Skopje, Republic of Macedonia
phone: + 389 2 310 40 00
fax: +389 2 31 04 021
www.alkaloid.com.mk

8. MARKETING AUTHORISATION NUMBER(S)

9. DATE OF FIRST MARKETING AUTHORIZATION/RENEWAL OF AUTHORIZATION

10. DATE OF REVISION OF THE TEXT